The positive results of PARADIGM-HF, along with evidence of improved cardiac biomarkers and remodeling with sacubitril-valsartan use in HFpEF patients, led to the PARAGON-HF trial.PARADIGM-HF, which evaluated sacubitril-valsartan vs enalapril in patients with heart failure with reduced ejection fraction (HFrEF), reported a decrease in mortality, risk of hospitalization for heart failure, symptoms and physical limitations in such patients.To date, there are no proven treatments to reduce the morbidity and mortality in patients with heart failure with preserved ejection fraction (HFpEF), with therapies mainly focused on symptomatic relief and treatment of co-existing conditions.for the PARAGON-HF Investigators and Committee Rizkala, Pharm.D., Jianjian Gong, Ph.D., Victor C. Kerr Saraiva, M.D., Małgorzata Lelonek, M.D., Bela Merkely, M.D., Michele Senni, M.D., Sanjiv J. Boytsov, M.D., Josep Comin-Colet, M.D., John Cleland, M.D., Hans-Dirk Düngen, M.D., Eva Goncalvesova, M.D., Tzvetana Katova, M.D., Jose F. Desai, M.D., M.P.H., Brian Claggett, Ph.D., Pardeep S. van Veldhuisen, M.D., Faiez Zannad, M.D., Michael R.
Pfeffer, M.D., Ph.D., Burkert Pieske, M.D., Margaret M. Maggioni, M.D., Felipe Martinez, M.D., Milton Packer, M.D., Marc A. Anand, M.D., D.Phil., Junbo Ge, M.D., Carolyn S.P. Table of contents for the PARAGON-HF Trial summary:Īngiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction This Journal Club focuses on the PARAGON-HF Trial. For more information, check out the CardioNerds Journal Club Page. The PA-ACC – CardioNerds Narratives in CardiologyĬardioNerds Journal Club is a monthly forum for CardioNerds to discuss and breakdown recent publications on twitter and are produced with a corresponding infographic and detailed blog post.
0 kommentar(er)
